World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
77
Citations
35695
World Ranking
18252
National Ranking
1658

Overview

Mary O'Brien is affiliated with the Royal Marsden NHS Foundation Trust in the United Kingdom. Their research centers primarily around medicine, with a focus on pulmonary and respiratory medicine, oncology, and cancer research. The scope of their work extends to radiology, nuclear medicine and imaging, as well as molecular biology.

The scientist has contributed extensively to studies related to lung cancer treatments and mutations, lung cancer diagnosis and treatment, cancer immunotherapy and biomarkers, cancer genomics and diagnostics, occupational and environmental lung diseases, lung cancer research studies, and pleural and pulmonary diseases.

Mary O'Brien has authored several recent papers, including:

  • "Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial" (2022) published in The Lancet Oncology
  • "The use of telepsychiatry during COVID-19 and beyond" (2020) published in Irish Journal of Psychological Medicine

Their frequent co-authors include:

  • Sanjay Popat
  • Anna Minchom
  • Jaishree Bhosle
  • Charlotte Milner-Watts
  • Nadia Yousaf

Mary O'Brien has published in a variety of venues, most notably:

  • Lung Cancer
  • Journal of Clinical Oncology
  • Annals of Oncology
  • European Journal of Cancer
  • Journal of Thoracic Oncology

Best Publications

  • Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

    Mary E R O'Brien;N. Wigler;M. Inbar;R. Rosso

  • Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

    A Webb;D Cunningham;J H Scarffe;P Harper

  • Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung Cancer

    Mary E.R. O'Brien;Tudor-Eliade Ciuleanu;Hristo Tsekov;Yaroslav Shparyk

  • Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score >= 50%

    Martin Reck;Delvys Rodríguez-Abreu;Andrew G. Robinson;Rina Hui

  • Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study

    Tom Treasure;Loic Lang-Lazdunski;David Waller;Judith M Bliss

  • Do Patients With Weight Loss Have a Worse Outcome When Undergoing Chemotherapy for Lung Cancers

    P J Ross;S Ashley;A Norton;K Priest

  • Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

    Corinne Faivre-Finn;Michael Snee;Linda Ashcroft;Wiebke Appel

  • Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.

    T J Powles;T F Hickish;A Makris;S E Ashley

  • Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial

    Karen Kelly;Nasser K. Altorki;Wilfried E.E. Eberhardt;Mary E.R. OBrien

  • Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin

    Ian E. Smith;Mary E.R. O’Brien;Denis C. Talbot;Marianne C. Nicolson

  • Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial

    Sally Moore;Jessica Corner;Jo Haviland;Mary Wells

  • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

    Julie R Brahmer;Delvys Rodríguez-Abreu;Andrew G Robinson;Rina Hui

  • Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer

    Joachim von Pawel;Robert Jotte;David R. Spigel;Mary E.R. O'Brien

  • Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

    Martin F Muers;Richard J Stephens;Patricia Fisher;Liz Darlison

  • Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.

    Armando Santoro;Mary E. O'Brien;Rolf A. Stahel;Kristiaan Nackaerts

  • Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

    Audrey Mauguen;Jean Pierre Pignon;Sarah Burdett;Caroline Domerg

  • Large-scale UK audit of blood transfusion requirements and anaemia in patients receiving cytotoxic chemotherapy.

    P J Barrett-Lee;N P Bailey;M E R O'Brien;E Wager

  • Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Anne Marie C. Dingemans;Anne Marie C. Dingemans;Lizza E.L. Hendriks;Thierry Berghmans;Antonin Levy

Frequent Co-Authors

Stanley W. Ashley
Stanley W. Ashley Brigham and Women's Hospital
Martin Reck
Martin Reck LungenClinic Grosshansdorf
David Cunningham
David Cunningham Royal Marsden NHS Foundation Trust
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Silvia Novello
Silvia Novello University of Turin
Paul Baas
Paul Baas Antoni van Leeuwenhoek Hospital
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Nir Peled
Nir Peled Hebrew University of Jerusalem
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in medicine opens doors to a wide range of healthcare careers beyond traditional medical practice. Many students are now considering related fields and advanced degrees through flexible online programs.

For those interested in hospital or clinic leadership roles, a cheapest master's in healthcare administration can be a smart option. This degree develops management skills required for high-level administrative positions in healthcare facilities.

Nurses seeking career advancement often pursue cheap dnp online programs. A Doctor of Nursing Practice (DNP) prepares graduates for leadership in clinical practice, education, or policy.

Aspiring pharmacists can explore the flexibility of pharm d online programs, earning their credentials for rewarding positions in pharmaceutical care.

Additionally, many choose non-clinical careers in data or information systems. A bachelor of health information management online prepares graduates for vital roles managing patient records and digital health infrastructure.

Online healthcare degrees offer affordability and flexibility, making it easier than ever to chart diverse and impactful career pathways in the medical field.

Best Scientists Citing Mary O'Brien

Trending Scientists

Recently Published Articles